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Passiflora cincinnata Masters is a Brazilian native species of passionflower. This genus is known in the American continent
folk medicine for its diuretic and analgesic properties. Nevertheless, few studies investigated possible biological effects of P.
cincinnata extracts. Further, evidence of antioxidant actions encourages the investigation of possible neuroprotective effects in
animal models of neurodegenerative diseases. This study investigates the effect of the P. cincinnata ethanolic extract (PAS) on mice
submitted to a progressive model of Parkinson’s disease (PD) induced by reserpine. Male (6-month-old) mice received reserpine
(0.1mg/kg, s.c.), every other day, for 40 days, with or without a concomitant treatment with daily injections of PAS (25mg/kg,
i.p.). Catalepsy, open field, oral movements, and plus-maze discriminative avoidance evaluations were performed across treatment,
and immunohistochemistry for tyrosine hydroxylase was conducted at the end. The results showed that PAS treatment delayed
the onset of motor impairments and prevented the occurrence of increased catalepsy behavior in the premotor phase. However,
PAS administration did not modify reserpine-induced cognitive impairments. Moreover, PAS prevented the decrease in tyrosine
hydroxylase immunostaining in the substantia nigra pars compacta (SNpc) induced by reserpine. Taken together, our results
suggested that PAS exerted a neuroprotective effect in a progressive model of PD.
1. Introduction
The genus Passiflora (Passifloraceae) comprises species noted
by their edible fruits, exotic flowers, and use in folk medicine
for sedative, anxiolytic, diuretic, and analgesic effects [1–5].
The phytochemical profile of the species of this genus is
complex. Phenols, cyanogenic glycosides, alkaloids, and
flavonoids can be found in their composition and can be
responsible for their pharmacological effects [2]. These
compounds could also be related to biological activities of
these plants such as anti-inflammatory [6], sedative [7],
antihyperglycemic [8], antiulcer [9], anxiolytic [10–13], and
antioxidant [9, 14–16] actions. David and colleagues [17]
reported higher antioxidant action and lower toxicity of the
Passiflora cincinnata methanolic extract when compared to
other plants fromBrazilianCaatinga. In addition,Wondracek
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and colleagues [18] detected carotenoids compounds such
as neoxanthin, trans-violaxanthin, antheraxanthin, lutein,
zeaxanthin, and trans-𝛽-carotene in the P. cincinnata fruit
pulp. In this respect, carotenoids can modulate intracellular
signaling cascades associated with inflammatory cytokines
and antioxidant enzymes production. These modulatory
activities lead to antioxidant, antiapoptotic, and anti-inflam-
matory effects that may represent an important improve-
ment in the treatment of neurodegenerative disorders
[19].
Neurodegenerative disorders such as Parkinson’s and
Alzheimer’s diseases show severe social and economic chal-
lenges, with high impact on public health systems around
the world. PD is a progressive and degenerative neurological
pathology, characterized by neuronal loss in multiple brain
regions, but mostly dopaminergic neurons in the substantia
nigra pars compacta (SNpc) [20, 21]. Additionally, the neu-
ropathology of this disease is characterized by the formation
of intraneuronal protein clusters of 𝛼-synuclein, referred to
as Lewy’s bodies [22–24].The degeneration in SNpc cells and
consequent dopaminergic depletion in the striatum result in
the classic motor symptoms of PD: resting tremor, rigidity,
postural instability, and bradykinesia [20, 25, 26].This deple-
tionmay be result of an imbalance between the production of
prooxidants (e.g., reactive oxygen species) and endogenous
antioxidant agents (e.g., catalase and glutathione), which
generates cellular machinery damage, leading to events such
as endoplasmic reticulum or mitochondrial dysfunctions,
protein degradation, and apoptosis [27].
Dopaminergic medications used in the treatment of
patients with Parkinson’s disease are associated with motor
and nonmotor behavioral side effects. The dopamine pre-
cursor 3,4-dihydroxyphenylalanine (levodopa or L-dopa) is
the most efficient treatment to control motor deficits of PD
patients [28, 29]. However, patients treatedwith levodopa (up
to 80%) develop side effects such as dyskinesia and motor
fluctuations due to the on-off effect [29–31]. In addition,
current available treatments do not reduce or preclude
neurodegeneration [32, 33].
Over the years, the use of animal models to evaluate
neurochemical and neuropathological aspects of PDhas been
critical to the understanding of PD’s etiology, as well as the
validation of potential treatments. The chronic administra-
tion of a low dose of reserpine (0.1mg/kg, s.c.) has been pro-
posed as a progressive pharmacological model of PD in rats
[34] and mice [35], mainly because this protocol gradually
provokes motor and nonmotor impairments mimicking the
progressive nature of the PD symptoms [36]. The alkaloid
reserpine induces monoamine depletion, oxidative stress,
inflammation, proapoptotic commitment, reduction in tyro-
sine hydroxylase levels, increase in 𝛼-synuclein immunos-
taining, and upregulation of DA receptors [36]. In addition,
this protocol induces progressive motor impairments pre-
ceded by cognitive deficits [35, 37], which is consistent with
the general development of the disease in humans.The aim of
the present study was to evaluate the effects of the ethanolic
extract of Passiflora cincinnata on motor, cognitive, and
neuronal parameters inmice submitted to repeated treatment
with reserpine.
2. Material and Methods
2.1. Ethanolic Extract Preparation. Leaves of Passiflora cincin-
nata were collected in Moita Bonita city, Sergipe state, Brazil.
Professionals from the University of Sergipe Herbarium
identified the specimen. A voucher specimen (ASE 11,112)
has been deposited in the herbarium of the institution for
reference. After identification, samples were dried at 37∘C in
an oven with air renewal and airflow for 48 h until complete
dehydration. The material was crushed with a knife mill and
subsequently powdered (293.3 g). Afterwards, it was extract-
ed by maceration at room temperature in 90% ethanol for
5 days. The extract was filtered in vacuum, and the solvent
was removed using a rotary evaporator (45∘C) under reduced
pressure and freeze-dried, yielding the ethanolic extract of the
PAS (EEPc). The percentage of EEPc yield was 35.2%.
2.2. Animals. Six-month-oldmale Swissmice were housed in
groups of 6–8 per cage (30 × 37 × 16 cm) under conditions of
acoustic isolation, controlled airflow and temperature (25 ±
1∘C), and a 12 h light/dark cycle (lights on 6:30 a.m.) with
food and water available ad libitum. Animals used in this
study were handled in accordance with Brazilian law for the
use of animals in research (Law Number 11.794) and the
local ethics committee for animal usage approved all the
procedures (Protocol CEUA/UFRN number 003/2013). All
efforts were made to minimize animal pain, suffering, or
discomfort during treatment.
2.3. Drugs Treatment and General Procedures. Reserpine
(RES, Sigma Chemical Co., USA) was dissolved in glacial
acetic acid (1%) and then diluted to the correct concentration
with distilled water. Vehicle consisted of the same amount
of acetic acid and water as in the reserpine solution. Both
reserpine and vehicle were injected subcutaneously (s.c.) in
a volume of 10mL/kg.
Before the beginning of experimental procedures, ani-
mals were gently handled for 10min for 5 consecutive days.
The apparatuses were cleaned with 5% alcohol solution
after each behavioral session and all behavioral data were
registered and analyzed by the video-tracking software Any-
maze (Stoelting, USA), except for the catalepsy test and the
oral movement’s evaluation that were manually registered by
researchers blind to treatment.
2.4. Experimental Design. Mice were randomly assigned to
one of four groups: CTR/CTR (𝑛 = 13), CTR/PAS (𝑛 = 15),
RES/CTR (𝑛 = 17), and RES/PAS (𝑛 = 16). Animals received
subcutaneous injections of vehicle (CTR) or 0.1mg/kg of
reserpine (RES) at a volume of 10mL/kg body weight, every
48 h for 40 days of treatment. Moreover, mice received daily
intraperitoneal injections of PAS vehicle (CTR) or 25mg/kg
of extract at a volume of 10mL/kg body weight for 40 days.
Animals did not show signs of intoxication, weight lost, pain,
or discomfort during the treatment, showing good biological
tolerability of the PAS ethanolic extract.
Animals were submitted to the following procedures
before the daily injections (between 8:00 a.m. and 4:00 p.m.):
(1) catalepsy test; (2) assessment of oral movements 48 h after
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Figure 1: Schematic representation of the neuroprotective evaluation of PAS administration in mice.
the 4th, 8th, 12th, 16th, and 20th injections; (3) discriminative
avoidance task 24 h before (training) and after (testing) the
10th injection; (4) evaluation of open field behavior 48 h
after the 20th injection. Experimental design is shown in
Figure 1.
2.5. Behavioral Tests
2.5.1. Catalepsy Test. The catalepsy behavior was assessed by
placing the animal’s forepaws on a horizontal bar positioned
5 cm above the bench surface. Catalepsy was defined as an
immobile posture (keeping both forepaws on the bar) and
was measured up to a maximum of 180 s. Three trials per
animal in each observation day were carried out, and the
results were analyzed considering the mean value of these
trials.
2.5.2. Oral Movements. Mice were individually placed in
a transparent glass box (20 × 20 × 15 cm) with mirrors
positioned under and behind it to allow behavioral quantifi-
cation when the animal faced away from the observer. The
frequency of vacuous chewing movement (mouth openings
in the vertical plane not directed toward physical material)
and duration (s) of twitching of the facial musculature were
measured continuously for 10min.
2.5.3. Plus-Maze Discriminative Avoidance Task (PMDAT).
The apparatus employed is a modified elevated plus-maze,
made of wood, containing two open arms (27.5 × 6.5 cm)
opposite to two enclosed arms (27.5 × 6.5 × 18 cm). One
lamp and one loudspeaker were placed over one of the
enclosed arms (aversive enclosed arm). In each side of the
apparatus, there were different extramaze visual cues that
animals could use to distinguish the location of different
arms of the maze. Two behavioral sessions were performed
in each experiment. During the training session, mice were
placed individually in the center of the apparatus facing the
open arms intercept and, over 10min, every time animals
entered in the aversive enclosed arm they received aversive
stimuli until leaving the arm. These aversive stimuli were
noise (80 dB) and light (100W). The test session was carried
out 24 h after the training session. In this test, mice were
again placed in the apparatus for 5min, without receiving
any aversive stimulation. Animals were considered to be in a
certain armwhen the four paws passed over its entrance [38].
In both sessions, the amount of time spent in each enclosed
arm (aversive and nonaversive) was registered and compared
in each group for learning andmemory evaluation.Moreover,
locomotor activity and anxiety-like behavior were evaluated
by total distance travelled in the apparatus and percentage
of time spent on open arms (% TOA, time spent in open
arms divided by the summation of time spent in open and
enclosed arms), respectively. Further, in the training session,
ethological components of risk assessment were evaluated
by the following parameters: head dipping (frequency of
movements of the head toward the floor), categorized into
protected head dipping (PHD, when performed from the
center of apparatus) and unprotected head dipping (UHD,
when performed from the open arms), and stretched attend
postures (SAP, defined by stretching and contraction of body
to its original position without locomotion).
2.5.4. Open Field. At the final day of the protocol animals
were submitted to the open field in order to evaluate locomo-
tor and exploratory activities. The apparatus was a circular
arena (50 cm in diameter) with 40 cm high walls, made of
wood and painted black. Animals were placed in the center
of the apparatus for free exploration during 10min. Distance
travelled in the whole arena (m), average speed (m/s), and
time spent in the center of the open field (s) were evaluat-
ed.
2.5.5. Tissue Processing. Upon completion of the behavioral
procedures, animals were deeply anesthetized with intraperi-
toneal injection of thiopental sodium (100mg/kg) and per-
fused transcardially with 100–150mL phosphate-buffered
saline (PBS), pH 7.4, containing 0.2% heparin, followed by
150mL PBS with 4% paraformaldehyde 0.1M. The brains
were removed from the skull and postfixed in the same
fixative solution previously described and stored at 4∘C. After
24 hours, we transferred the brains to a solution containing
sucrose 30%0.1MPBS, at 4∘C. Each brainwas fixed inTissue-
Tek (Sakura, Japan) at −20∘C. Then we serially sliced the
brains in the coronal plane into 30𝜇m thick sections with
a cryostat microtome (Leica, Germany) at a temperature of
−20∘C.
2.5.6. Tyrosine Hydroxylase (TH) Immunohistochemistry.
Following tissue processing, we performed immunohisto-
chemistry for TH, using a free-floating protocol. Sections
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were washed out 4 times with PBS (pH 7.4) for 5min each and
consecutively washed with 0.3% H2O2 solution for 20min
to reduce endogenous peroxidase activity. For the detection
of TH, sections were incubated with rabbit anti-tyrosine
hydroxylase polyclonal antibody (cat # AB152 Chemicon,
USA, 1 : 10,000).The antibodywas diluted in triton x-100 0.4%
and PBS with 2% albumin serum, for 18–24 h at room
temperature. Afterwards, sections were incubated with goat
biotinylated anti-rabbit IgG (Vector Labs, USA, 1 : 5,000)
diluted with triton x-100, 0.4% NaCl, and PBS for 2 h at
room temperature. Then, a new washout process was carried
out followed by an incubation with avidin-biotin-peroxidase
solution (ABC Elite kit, Vector Labs, Burlingame, USA). The
reaction was developed by adding of 3,3-diaminobenzidine
(DAB, Sigma-Aldrich, USA) and 0.01% H2O2 0.1M phos-
phate buffer solution for 1-2min. Then, we left sections to
dry, dehydrated in a graded alcohol series, cleared in xylene,
and coverslipped with Entellan (Merck). All sections were
immunostained concomitantly, to minimize possible back-
ground differences between samples. Sectionswere examined
under brightfield illumination with an optical microscope
(Nikon Eclipse Ni-E), attached with a digital camera (Motic
5.0) to record images.
In order to estimate the number of TH+ cells in SNpc
and TH levels in striatum, four sections of each animal were
selected for each region evaluated (SNpc and striatum, 𝑛 =
4–7 per group): one at the rostral level, two at medium level,
and one at caudal level, representative of the rostrocaudal
extension of each area of interest. The exact location of the
regions was determined on the basis of the Paxinos and
Franklin [39] mice brain atlas.These sections were chosen by
a systematic sampling and all measurements were performed
in a blindmanner. All TH+ cells of SNpc on each sectionwere
counted and the mean of the four measures was registered.
Additionally, TH+ levels in striatum fibers were assessed by
analysis of relative optical densitometry (ROD), using ImageJ
software (version 1.48, NIH, USA). For this purpose, we
transform our images in 8-bit color grade (i.e., grayscale),
and four random fields were chosen in the target area (dorsal
striatum). The mean values of gray level in the target areas
were subtracted from themean value of a control region (used
to assess “noise” or nonspecific staining, i.e., cortex or corpus
calosum). Finally, all values were normalized considering the
control group mean value, in order to evaluate proportional
alterations.
2.6. Statistical Analysis. Data normality and the homogeneity
of varianceswere, respectively, tested by the Shapiro-Wilk and
Levene’s tests. All comparisons among groups for locomotor
parameters and anxiety-like behaviors from PMDAT were
performed by one-way ANOVA followed by Dunnett’s test,
whereas learning and memory parameters were analyzed
by the paired-samples 𝑡-test. Catalepsy behavior and oral
movements were compared between groups across treatment
period using ANOVA with repeated measures followed by
Tukey’s test. In the open field test, parameters were compared
between groups using one-way ANOVA followed by Tukey’s
test. Results were expressed as mean± SEM and 𝑝 < 0.05was
considered to reflect significant differences.
3. Results
3.1. Catalepsy Behavior. ANOVA with repeated measures
revealed time versus treatment interaction [𝐹(20,60) = 6.365,
𝑝 < 0.001]. Post hoc analysis showed that repeated treatment
with reserpine induced progressive increase in the duration
of catalepsy behavior, with RES-treated animals being signifi-
cantly different from control group from the 26th (RES/CTR)
and the 30th (RES/PAS) days onwards (see Figure 2(a)). No
differences were found considering chronic administration of
PAS per se (CTR/PAS). To clarify the differences between the
groups we subdivided the treatment length in three phases:
basal (beginning of procedures to 12th day), premotor (14th
to 26th day), and motor (28th to 40th day) phases. This
new analysis, now subdivided by phases, revealed time ×
treatment interactions for premotor [𝐹(6,18) = 4,942, 𝑝 <
0.001] and motor phases [𝐹(6,18) = 3,534, 𝑝 < 0.001]. Post
hoc analysis revealed significant increased catalepsy in RES/
CTR compared to CTR/CTR and RES/PAS groups in the
premotor phase (Figure 2(c)). In the motor phase both RES/
CTR and RES/PAS groups showed increased catalepsy time
when compared to CTR/CTR group (Figure 2(d)).
3.2. Oral Movements. ANOVA with repeated measures re-
vealed effect of treatment [𝐹(3,55) = 14.112, 𝑝 < 0.001] for
duration of oral twitching. We found a significant increase in
RES/CTR group when compared to CTR on the 16th (48 h
after the 8th injection, 𝑝 < 0,01) and 40th (48 h after the 20th
injection, 𝑝 < 0,01) days, and RES/PAS group showed in-
crease in 16th, 24th, and 40th days (𝑝 < 0,01) (Figure 3(a)).
For number of vacuous chewing movements, ANOVA
with repeatedmeasures revealed time× treatment interaction
[𝐹(4,12) = 2.247, 𝑝 < 0.05]. Indeed, animals receiving reser-
pine (RES/CTR and RES/PAS) showed a significant increase
when compared to control groups in all assessment days
(Figure 3(b)).
3.3. Plus-Maze Discriminative Avoidance Task (PMDAT). No
differences were found in total distance travelled in the
training [𝐹(3,26) = 1.708, 𝑝 = 0.193] and test [𝐹(3,26) = 1.672,
𝑝 = 0.201] sessions (Table 1).
No differences were found in % TOA [𝐹(3,26) = 0.407, 𝑝 =
0.749], UHD [𝐹(3,26) = 1.291, 𝑝 = 0.301], and PHD [𝐹(3,26) =
2.171, 𝑝 = 0.119]. However, one-way ANOVA revealed an
increase in CTR/PAS values of SAP [𝐹(3,26) = 3.175, 𝑝 < 0.05]
when compared to the CTR/CTR group (Table 1).
In the training session, paired-samples 𝑡-test showed that
all groups spent more time in the nonaversive enclosed arm
indicating that all animals learned the task [CTR/CTR: 𝑡(3) =
4.501, 𝑝 < 0.05, CTR/PAS: 𝑡(5) = 3.090, 𝑝 < 0.05, RES/CTR:
𝑡(7) = 6.404, 𝑝 < 0.001, and RES/PAS: 𝑡(8) = 7.903,
𝑝 < 0.001] (Figure 4(a)). However, in the test session, only
CTR/CTR and CTR/PAS groups remembered the learned
task [CTR/CTR 𝑡(3) = 4.107, 𝑝 < 0.05, CTR/PAS 𝑡(5) = 2.302,
𝑝 = 0.07] (Figure 4(b)).
3.4. Open Field Test. In this test, no differenceswere found for
total distance travelled [𝐹(3,55) = 2.670, 𝑝 = 0.057] and time
spent in the center of open field [𝐹(3,55) = 0.322, 𝑝 = 0.809].
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Figure 2: Effects of repeated administration of Passiflora cincinnata extract (25mg/kg) and reserpine (0.1mg/kg) on catalepsy behavior of
mice. (a) Entire treatment analysis, (b) basal phase, (c) premotor phase, and (d) motor phases. Data are expressed as mean ± SEM. ∗𝑝 < 0.05
RES/CTR compared to CTR/CTR; #𝑝 < 0.05 RES/PAS compared to CTR/CTR; and +𝑝 < 0.05 RES/CTR compared to RES/PAS (repeated
measures ANOVA followed by Tukey’s post hoc test).
Table 1: Effects of repeated administration of Passiflora cincinnata (25mg/kg) and reserpine (0.1mg/kg) on total distance travelled (training
and test sessions) and anxiety-like parameters (training session) in plus-maze discriminative avoidance task.
Treatment Total distance travelled (meters) Anxiety-like parameters (frequency)
Training Test % TOA SAP PHD UHD
CTR/CTR 11.82 ± 2.99 9.41 ± 4,04 7.27 ± 2.74 26.25 ± 2.50 5.75 ± 1.38 8.00 ± 3.70
CTR/PAS 14.23 ± 2.50 9.56 ± 3.24 19.58 ± 5.63 42.50 ± 4.06∗ 14.17 ± 4.44 24.00 ± 9.47
RES/CTR 9.64 ± 1.20 4.96 ± 1.68 18.92 ± 10.80 38.38 ± 3.02 6.63 ± 1.66 10.38 ± 3.22
RES/PAS 9.41 ± 1.09 4.18 ± 0.86 14.13 ± 4.52 35.44 ± 2.76 8.22 ± 1.28 17.78 ± 5.27
Data expressed asmean ± SEM. ∗𝑝 < 0.05 compared to CTR/CTR (one-way ANOVA followed by Tukey’s post hoc test).% TOA: percentage of time spent on
open arms, SAP: stretched attend postures, PHD: protected head dipping, UHD: unprotect head dipping.
However, reserpine groups (RES/CTR and RES/PAS) showed
a decrease in the average speed [𝐹(3,55) = 7.152, 𝑝 < 0.001]
(Figure 5).
3.5. Tyrosine Hydroxylase Immunohistochemistry. For the
number of TH+ cells in SNpc, one-way ANOVA revealed
significant differences between groups [𝐹(3,21) = 7.329, 𝑝 <
0.005]. Post hoc analysis revealed a decrease in the number
of TH+ cells on RES/CTR when compared to CTR/CTR
group as well as an increase on RES/PAS when compared to
RES/CTR group (Figure 6(a)). No differences were found in
relative optical density of dorsal striatum [𝐹(3,21) = 0.268,
𝑝 = 0.847] (Figure 6(b)).
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Figure 3: Effects of repeated administration of Passiflora cincinnata extract (25mg/kg) and reserpine (0.1mg/kg) on oral movements of mice.
(a) Twitching and (b) vacuous chewing. Data are expressed as mean ± SEM. ∗𝑝 < 0.05 RES/CTR compared to CTR/CTR; #𝑝 < 0.05 RES/PAS
compared to CTR/CTR (repeated measures ANOVA followed by Tukey’s post hoc test).
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Figure 4: Effects of repeated administration of Passiflora cincinnata extract (25mg/kg) and reserpine (0.1mg/kg) on mice exploration of the
aversive and nonaversive arms in plus-maze discriminative avoidance task. (a) Training session and (b) test session. Data are expressed as
mean ± SEM. ∗𝑝 < 0.05 and #𝑝 = 0.07 compared to aversive arm (paired-samples 𝑡-test).
4. Discussion
In this study, we investigated the effects of the administration
of the ethanolic extract of P. cincinnata on reserpine-induced
parkinsonism. Our main results showed that mice chroni-
cally treated with PAS displayed a delayed onset of motor
impairments induced by reserpine, but the treatment did not
modify reserpine-induced cognitive impairment. In addition,
concomitant PAS treatment prevented the depletion of TH+
SNpc cells caused by the chronic administration of reserpine.
Reserpine administration induces depletion of mono-
amines by blocking vesicular monoamines transporters
(VMATs), which results in motor disturbances like tremor,
rigidity, and hypokinesia [40–42]. This blockage of VMATs
generates a cytoplasmic accumulation and further decrease
of neurotransmitters release. Moreover, monoamines left in
cytoplasm are metabolized, generating reactive metabolites,
which leads to oxidative stress [43–46]. Thus, it seems to be
an appropriate animal model for development of new drugs
for treatment of PD [47, 48].
The majority of studies using reserpine as a PD model
focus on a single high dose administration [49–52]. In an
attempt to mimic the PD’s progressive profile, a recent study
from our group demonstrated that chronic administration of
a low dose of reserpine was able to induce progressive
motor impairment, accompanied by lipid peroxidation due
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Figure 5: Effects of repeated administration of Passiflora cincinnata extract (25mg/kg) and reserpine (0.1mg/kg) on (a) total distance
travelled, (b) time spent in central zone, and (c) average speed of mice in open field. Data are expressed as mean ± SEM. ∗∗𝑝 < 0.01 and
∗∗∗𝑝 < 0.005 compared to control (one-way ANOVA followed by Tukey’s post hoc test).
to oxidative stress [34] and tyrosine hydroxylase depletion
in dorsal striatum and SNpc [37]. In the present study, we
used an adaptation of this protocol to mice, as described by
Campeˆlo and colleagues [35]. Specifically, there is an increase
in the treatment duration; that is, the number of injections
was altered from 10 to 20 (during 40 days). This adaptation
is necessary because mice are more resilient to reserpine
than rats. A possible explanation to this resilience is the fact
that mice have less monoamine oxidase (MAO) activity in
the brain compared to rats [53], which could contribute to
a lower formation of oxidative metabolites from dopamine
degradation (e.g., hydrogen peroxide). Furthermore, these
physiologic differences may also be responsible for the
minor decrease in TH+ SNpc cells (this reduction is more
expressive in rats), and consequently no reduction of striatal
densitometry, whichmight have mitigate possible PAS effects
(Figure 6(b)). We suggest that this result may be related to a
compensatory mechanism. In this respect, previous studies
have reported that remaining dopaminergic neurons in SNpc
could sustain a more intense expression of TH to replace the
new dopamine demand in their terminals, converting more
tyrosine into dopamine [54]. This new dopamine demand
would occur in response to reserpine action on VMAT,
leading to the sustained expression of TH densitometry levels
reported in dorsal striatum of reserpine groups.
Interestingly, the administration of the ethanolic extract
of P. cincinnata delayed the onset of the motor impairment
(increased catalepsy behavior) induced by reserpine treat-
ment. Indeed, while RES/CTR group showed motor deficits
from the 26th day after the beginning of treatment, the
impairment was present in the RES/PAS group only from
the 30th day onwards (Figure 2). Furthermore, the coadmin-
istration with PAS also prevented the tyrosine hydroxylase
depletion in the SNpc cells, which occurred in the RES/CTR
group (Figure 6(a)). Nevertheless, reserpine-treated animals
also showed reduction in average speed in open field locomo-
tion (Figure 5(c)) and increased oral twitching and vacuous
chewing movements (Figure 3), which were not prevented by
PAS cotreatment.
Some studies have demonstrated the neuroprotective
activity of antioxidant compounds in animals treated with
reserpine. The antioxidant substances (e.g., ebselen and vita-
mins E and C) reduced oxidative stress parameters such as
thiobarbituric acid reactive substances (TBARS) and catalase
levels [55–57]. In this context, an earlier research showed
that P. cincinnata has an antioxidant activity [17]. Based on
this report, we speculate another mechanism underlying this
antioxidant effect. It is known that flavonoids may trigger
an internal cellular response through the activation of the
PKC/ARE/Nrf2 pathway [58]. This signaling promotes tran-
scription of NAD(P)H:quinone oxidoreductase-1 (NQO1)
and other detoxifying genes [59], which is impaired by
reserpine treatment because it decreases PKC activity [60].
Consequently, we could infer that this characteristic is
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Figure 6: Effects of repeated administration of Passiflora cincinnata extract (25mg/kg) and reserpine (0.1mg/kg) on (a) TH+ cells of SNpc
and (b) relative optical density (ROD) of dorsal striatum, both normalized by CTR values. Data are expressed as mean ± SEM. ∗𝑝 < 0.05
compared to CTR/CTR. #𝑝 < 0.05 compared to RES/CTR. (one-way ANOVA followed Tukey’s post hoc test). Magnification 100x (a) and
40x (b), black bold lines are scale bars, corresponding to 200𝜇m.
responsible for the delay in the onset of motor deficits in the
catalepsy test, as well as the decrease in tyrosine hydroxylase
depletion in SNpc cells.
As mentioned above, in this PD model a more reduction
in TH+ SNpc cells is observed in rats than inmice.Therefore,
the PAS effects in the striatum would be better detectable if
mice showed an expressive reduction of TH+ cells. In other
words, it is possible that different metabolism rates between
species may have overshadowed the results regarding TH
levels in the striatal dopaminergic projections. Nevertheless,
it the TH+ cell count in the SNpc did reduce after reserpine
treatment, and PAS was able to prevent it.
Regarding the oral movements evaluation, it is impor-
tant to highlight the differences found in the sensitivity
of both parameters to the effects of reserpine treatment.
Both parameters were able to detect motor deficits in the
beginning of the treatment, even before the appearance of
catalepsy increment. However, the effect of time and the
interaction between time and treatment were only observed
for vacuous chewing, a motor alteration well established in
the literature as a consequence of reserpine treatment [34, 55,
61–63]. Regardless, development of those impairments in our
animals were not prevented or delayed by PAS treatment.
Regarding cognitive evaluation in the PMDAT,we did not
observe any changes in learning, since all groups were able
to discriminate the aversive and the nonaversive arms during
the training session (Figure 4(a)). On the other hand, in the
test session, reserpine groups had a retrieval deficit, which
was not affected by cotreatment with PAS (Figure 4(b)). The
memory impairment in animals that received reserpine
corroborates previous data from our group [64, 65] and other
reports [66, 67]. This impairment might be compared to
recognition or evaluation deficits present in patients with
PD. Studies proposed that these changes are linked to an
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imbalance in basal ganglia dopamine availability.This imbal-
ance affects circuit connections to regions related to cognitive
and emotional functions, like prefrontal cortex, amygdala,
hippocampus, and ventral tegmental area, among other
regions [68–71]. Importantly, similar to the evaluation of oral
movements, cotreatment with PAS did not alter reserpine-
induced memory deficit. Taken together, these two findings
suggest that the protocol of PAS treatment used here was
not fully effective in preventing all alterations related to
reserpine-induced parkinsonism.
In addition, although PAS treatment did not improve
other parameters, the positive effects observed in catalepsy
behavior and tyrosine hydroxylase expression are relevant
because they suggest a potential delay in the neurodegener-
ation caused by PD. The use of this chronic treatment with a
low dose of reserpine, a well established model for PD [36],
positively contributed to demonstrating the subtle effect of
PAS that might not be evidenced in acute treatment with
neurotoxins (the usual method of PD inducement in rodent
models). We believe that a preventive (i.e., before reserpine
injections) treatmentwith PAS, increased doses of the extract,
or longer treatments could have a more widespread effect.
Alternatively, the application of fractions as well as isolated
P. cincinnata compounds could also be more effective.
Regarding possible effects on anxiety-like behavior, no
differences were found in relation to percentage of time in
open arms (Table 1), but studies have demonstrated that the
evaluation of risk assessment behavior (stretched attend pos-
ture and head dipping) may be useful in anxiety evaluation
[72, 73]. In the present study, we observed an increase in the
anxiety level (stretched attend postures frequency, Table 1) in
animals treated with PAS extract (training session), and this
effect could be responsible for the slight performance reduc-
tion presented in memory retrieval by this group, although it
was not significantly different from control (Figure 4(b)).
5. Conclusions
In summary, this research suggests that the ethanolic extract
of P. cincinnata has neuroprotective properties that may have
therapeutic potential for PD. Based on the literature, this
effect is probably related to an antioxidant-related action (see
above). However, further studies are required to assess the
range of these effects regarding parkinsonian symptoms, as
well as to determine the structure of active compounds and
their mechanisms of action.
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